The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Impavido     2-(hexadecoxy-oxido- phosphoryl)oxyethyl...

Synonyms: Miltefos, Miltex, Miltefosina, Miltefosine, HDPC, ...
This record was replaced with 3600.
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of SPBio_000777

 

High impact information on SPBio_000777

 

Chemical compound and disease context of SPBio_000777

 

Biological context of SPBio_000777

 

Anatomical context of SPBio_000777

 

Associations of SPBio_000777 with other chemical compounds

 

Gene context of SPBio_000777

 

Analytical, diagnostic and therapeutic context of SPBio_000777

References

  1. Miltefosine for visceral leishmaniasis. Eibl, H. N. Engl. J. Med. (2000) [Pubmed]
  2. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. Jha, T.K., Sundar, S., Thakur, C.P., Bachmann, P., Karbwang, J., Fischer, C., Voss, A., Berman, J. N. Engl. J. Med. (1999) [Pubmed]
  3. Miltefosine in recurrent cutaneous breast cancer. Clive, S., Leonard, R.C. Lancet (1997) [Pubmed]
  4. Transcriptional activation of p21(waf1/cip1) by alkylphospholipids: role of the mitogen-activated protein kinase pathway in the transactivation of the human p21(waf1/cip1) promoter by Sp1. De Siervi, A., Marinissen, M., Diggs, J., Wang, X.F., Pages, G., Senderowicz, A. Cancer Res. (2004) [Pubmed]
  5. Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine. Hanson, P.K., Malone, L., Birchmore, J.L., Nichols, J.W. J. Biol. Chem. (2003) [Pubmed]
  6. Drug resistance in leishmaniasis. Croft, S.L., Sundar, S., Fairlamb, A.H. Clin. Microbiol. Rev. (2006) [Pubmed]
  7. A pathway for phosphatidylcholine biosynthesis in Plasmodium falciparum involving phosphoethanolamine methylation. Pessi, G., Kociubinski, G., Mamoun, C.B. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  8. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Ruiter, G.A., Zerp, S.F., Bartelink, H., van Blitterswijk, W.J., Verheij, M. Cancer Res. (1999) [Pubmed]
  9. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Uberall, F., Oberhuber, H., Maly, K., Zaknun, J., Demuth, L., Grunicke, H.H. Cancer Res. (1991) [Pubmed]
  10. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. Pérez-Victoria, F.J., Sánchez-Cañete, M.P., Castanys, S., Gamarro, F. J. Biol. Chem. (2006) [Pubmed]
  11. Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide. Stekar, J., Hilgard, P., Klenner, T. Eur. J. Cancer (1995) [Pubmed]
  12. Effect of ether lipids on mouse granulocyte-macrophage progenitor cells. Vehmeyer, K., Kim, D.J., Nagel, G.A., Eibl, H., Unger, C. Cancer Chemother. Pharmacol. (1989) [Pubmed]
  13. Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography. Brochez, V., Van Heuverswyn, D., Diniz, J.A., De Potter, C.R., Van den Eeckhout, E.G. Lipids (1999) [Pubmed]
  14. Differential effects of all-trans-retinoic acid, docosahexaenoic acid, and hexadecylphosphocholine on cisplatin-induced cytotoxicity and apoptosis in a cisplantin-sensitive and resistant human embryonal carcinoma cell line. Timmer-Bosscha, H., de Vries, E.G., Meijer, C., Oosterhuis, J.W., Mulder, N.H. Cancer Chemother. Pharmacol. (1998) [Pubmed]
  15. Antitumor effects of alkylphosphocholines in different murine tumor models: use of liposomal preparations. Zeisig, R., Fichtner, I., Arndt, D., Jungmann, S. Anticancer Drugs (1991) [Pubmed]
  16. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. Pérez-Victoria, F.J., Gamarro, F., Ouellette, M., Castanys, S. J. Biol. Chem. (2003) [Pubmed]
  17. The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro. Verma, N.K., Dey, C.S. Diabetologia (2006) [Pubmed]
  18. Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Walochnik, J., Duchêne, M., Seifert, K., Obwaller, A., Hottkowitz, T., Wiedermann, G., Eibl, H., Aspöck, H. Antimicrob. Agents Chemother. (2002) [Pubmed]
  19. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Verma, N.K., Dey, C.S. Antimicrob. Agents Chemother. (2004) [Pubmed]
  20. Miltefosine Affects Lipid Metabolism in Leishmania donovani Promastigotes. Rakotomanga, M., Blanc, S., Gaudin, K., Chaminade, P., Loiseau, P.M. Antimicrob. Agents Chemother. (2007) [Pubmed]
  21. Hexadecylphosphocholine inhibits translocation of CTP:choline-phosphate cytidylyltransferase in Madin-Darby canine kidney cells. Geilen, C.C., Wieder, T., Reutter, W. J. Biol. Chem. (1992) [Pubmed]
  22. Growth inhibition of human mammary carcinoma by liposomal hexadecylphosphocholine: Participation of activated macrophages in the antitumor mechanism. Eue, I. Int. J. Cancer (2001) [Pubmed]
  23. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. Murray, H.W., Delph-Etienne, S. J. Infect. Dis. (2000) [Pubmed]
  24. Vesicle-mediated phosphatidylcholine reapposition to the plasma membrane following hormone-induced phospholipase D activation. Coletti, D., Silvestroni, L., Naro, F., Molinaro, M., Adamo, S., Palleschi, S. Exp. Cell Res. (2000) [Pubmed]
  25. Interaction between Miltefosine and Amphotericin B: Consequences for Their Activities towards Intestinal Epithelial Cells and Leishmania donovani Promastigotes In Vitro. M??nez, C., Buyse, M., Besnard, M., Farinotti, R., Loiseau, P.M., Barratt, G. Antimicrob. Agents Chemother. (2006) [Pubmed]
  26. Antagonism of phorbol-ester-stimulated phosphatidylcholine biosynthesis by the phospholipid analogue hexadecylphosphocholine. Wieder, T., Geilen, C.C., Reutter, W. Biochem. J. (1993) [Pubmed]
  27. Bcl-2 plays a key role instead of mdr1 in the resistance to hexadecylphosphocholine in human epidermoid tumor cell line KB. Fu, D., Shi, Z., Wang, Y. Cancer Lett. (1999) [Pubmed]
  28. Mumps virus can suppress the effective augmentation of HPC-induced apoptosis by IFN-gamma through disruption of IFN signaling in U937 cells. Hariya, Y., Yokosawa, N., Yonekura, N., Kohama, G., Fuji, N. Microbiol. Immunol. (2000) [Pubmed]
  29. Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity. Lucas, L., Hernández-Alcoceba, R., Penalva, V., Lacal, J.C. Oncogene (2001) [Pubmed]
  30. Miltefosine (Hexadecylphosphocholine) Inhibits Cytochrome c Oxidase in Leishmania donovani Promastigotes. Luque-Ortega, J.R., Rivas, L. Antimicrob. Agents Chemother. (2007) [Pubmed]
  31. Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Rybczynska, M., Spitaler, M., Knebel, N.G., Boeck, G., Grunicke, H., Hofmann, J. Biochem. Pharmacol. (2001) [Pubmed]
  32. Trial of oral miltefosine for visceral leishmaniasis. Sundar, S., Rosenkaimer, F., Makharia, M.K., Goyal, A.K., Mandal, A.K., Voss, A., Hilgard, P., Murray, H.W. Lancet (1998) [Pubmed]
  33. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. Leonard, R., Hardy, J., van Tienhoven, G., Houston, S., Simmonds, P., David, M., Mansi, J. J. Clin. Oncol. (2001) [Pubmed]
  34. Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine. Murray, H.W. Antimicrob. Agents Chemother. (2000) [Pubmed]
 
WikiGenes - Universities